Kelun Pharma receives approval for cefazolin injection

Sichuan Kelun Pharmaceutical (SZSE:002422) announced that its subsidiary, Hunan Kelun Pharmaceutical, has received drug registration approval from the National Medical Products Administration (NMPA) for its Cefazolin Sodium/Sodium Chloride Injection. Classified as a Category 3 chemical drug, the injection is designed as a dual-chamber bag product, separating powder and liquid components for enhanced stability and ease of use. The approval signifies Kelun's entrance into the dual-chamber infusion solution market, and the company is now the second domestic manufacturer approved for this packaging of cefazolin injection. The company notes that in 2024, China's Cefazolin Sodium injection sales reached CNY 1.35 billion. This drug is the eleventh product approval based on the dual-chamber bag platform. The company noted the possibility of unforeseen market factors affecting the commercial launch and sales of the product.